We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Detection of ctDNA Can Guide Post-Surgical Treatment of Colon Cancer Patients

By LabMedica International staff writers
Posted on 09 Jun 2022

Circulating tumor DNA (ctDNA) has been shown to be a biomarker that can predict whether, following surgical removal of the tumor, a stage II colon cancer patient can safely forgo chemotherapy without risk of recurrence of the disease

Stage II colon cancer is defined as a cancer that has grown through the wall of the colon, but does not extend to the lymph nodes or other organs. More...

While most patients with stage II colon cancer are cured after surgery to remove the cancer from the bowel, the cancer will recur in around 20% of patients. Currently, [at least in Australia] chemotherapy, with its frequent unpleasant side-effects, is offered to all stage II colon cancer patients despite a majority not actually needing it.

Previous studies have demonstrated that the presence of ctDNA after surgery to remove a tumor from the colon predicted very poor recurrence-free survival, whereas its absence predicted a low risk of recurrence. Based on these findings, investigators at the Walter and Eliza Hall Institute (Melbourne, Australia) and Johns Hopkins University (Baltimore, MD, USA) conducted a trial to assess whether a ctDNA-guided approach could reduce the use of chemotherapy without compromising recurrence risk.

In this study, 455 stage II colon cancer patients were randomly assigned to ctDNA-guided management (302 patients) or to standard management (153 patients). For ctDNA-guided management, a ctDNA-positive result at four or seven weeks after surgery prompted oxaliplatin-based or fluoropyrimidine chemotherapy. Patients who were ctDNA-negative were not treated.

Results revealed that 37 months after surgery a lower percentage of patients in the ctDNA-guided group than in the standard-management group received chemotherapy (15% vs. 28%). In the evaluation of two-year recurrence-free survival, ctDNA-guided management was as effective as standard management (93.5% and 92.4%, respectively; absolute difference, 1.1%). Three-year recurrence-free survival was 86.4% among ctDNA-positive patients who received adjuvant chemotherapy and 92.5% among ctDNA-negative patients who did not.

First author, Dr. Jeanne Tie, associate professor of medical oncology at the Walter and Eliza Hall Institute, said, “We found that when a patient’s blood test does not reveal ctDNA after colon surgery, the likelihood of micrometastases is very low and chemotherapy can be avoided as there are no tumor fragments left to kill. Our trial has conclusively shown how the ctDNA blood test can be used to direct post-surgical therapy in stage II colon cancer and substantially reduce the number of patients treated with chemotherapy, without impacting the risk of cancer relapse. While chemotherapy can be essential and lifesaving, many patients are receiving the treatment and its associated toxicities without any benefit.”

The ctDNA study was published in the June 4, 2022, online edition of The New England Journal of Medicine.

Related Links:
Walter and Eliza Hall Institute 
Johns Hopkins University 

 


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Pan-Cancer Panel
TruSight Oncology 500
New
Staining System
RAL DIFF-QUIK
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The Volition Nu.Q nucleosome assay runs on the IDS i10 automated analyzer platform (Photo courtesy of VolitionRx)

Groundbreaking Lateral Flow Test Quantifies Nucleosomes in Whole Venous Blood in Minutes

Diagnosing immune disruptions quickly and accurately is crucial in conditions such as sepsis, where timely intervention is critical for patient survival. Traditional testing methods can be slow, expensive,... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.